Sportradar Group (NASDAQ:SRAD – Free Report) had its price target reduced by Guggenheim from $26.00 to $23.00 in a research report sent to investors on Wednesday morning,Benzinga reports. Guggenheim currently has a buy rating on the stock. Several other research analysts have also weighed in on SRAD. BTIG Research lowered Sportradar Group from a “buy” […]

ADTRAN (NASDAQ:ADTN – Get Free Report) had its price objective decreased by equities research analysts at Needham & Company LLC from $14.00 to $9.00 in a report released on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the communications equipment provider’s stock. Needham & Company LLC‘s price target points to a potential […]

Core Scientific (NASDAQ:CORZ – Free Report) had its price objective lowered by B. Riley Financial from $42.00 to $31.00 in a research report released on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. CORZ has been the topic of several other reports. Keefe, Bruyette & Woods upgraded Core Scientific from […]

Alphabet (NASDAQ:GOOGL – Free Report) had its target price trimmed by Rosenblatt Securities from $410.00 to $380.00 in a report published on Thursday,Benzinga reports. They currently have a buy rating on the information services provider’s stock. A number of other analysts have also issued reports on the stock. Needham & Company LLC reissued a “buy” […]

Ross Stores (NASDAQ:ROST – Get Free Report) had its price target cut by equities research analysts at Bank of America from $265.00 to $258.00 in a research report issued on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the apparel retailer’s stock. Bank of America‘s price objective points to a potential upside […]

Avalo Therapeutics (NASDAQ:AVTX – Free Report) had its price target decreased by BTIG Research to $10.00 in a report released on Friday, Marketbeat.com reports. BTIG Research currently has a buy rating on the stock. Several other brokerages have also weighed in on AVTX. Weiss Ratings raised Avalo Therapeutics from a “sell (e+)” rating to a […]